Theravance Biopharma Inc (NASDAQ:TBPH) Given Average Recommendation of “Buy” by Brokerages

Shares of Theravance Biopharma Inc (NASDAQ:TBPH) have received a consensus recommendation of “Buy” from the eleven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $35.00.

Several equities analysts have recently issued reports on TBPH shares. ValuEngine raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a report on Saturday. Morgan Stanley started coverage on shares of Theravance Biopharma in a report on Monday, June 15th. They issued an “equal weight” rating and a $30.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of Theravance Biopharma in a report on Tuesday, July 7th. They issued an “overweight” rating and a $29.00 price objective for the company. Zacks Investment Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating and set a $34.00 price objective for the company. in a report on Tuesday, May 12th. Finally, Cowen started coverage on shares of Theravance Biopharma in a report on Wednesday, May 13th. They issued an “outperform” rating and a $42.00 price objective for the company.

Shares of TBPH traded down $0.77 during midday trading on Tuesday, hitting $19.42. 349,687 shares of the stock traded hands, compared to its average volume of 316,783. Theravance Biopharma has a 1-year low of $15.72 and a 1-year high of $31.54. The firm has a market capitalization of $1.23 billion, a PE ratio of -4.47 and a beta of 1.43. The business’s 50 day moving average price is $21.77 and its two-hundred day moving average price is $24.86.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.33). The firm had revenue of $19.86 million for the quarter, compared to the consensus estimate of $18.02 million. As a group, equities analysts forecast that Theravance Biopharma will post -3.87 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Theravance Biopharma by 30.5% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,495 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 816 shares during the period. First Quadrant L P CA acquired a new stake in shares of Theravance Biopharma in the second quarter worth $81,000. UBS Group AG grew its stake in shares of Theravance Biopharma by 77.3% in the first quarter. UBS Group AG now owns 4,478 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 1,953 shares during the last quarter. Amalgamated Bank acquired a new stake in shares of Theravance Biopharma in the fourth quarter worth $208,000. Finally, Principal Financial Group Inc. grew its stake in shares of Theravance Biopharma by 4.5% in the first quarter. Principal Financial Group Inc. now owns 8,640 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 373 shares during the last quarter. Hedge funds and other institutional investors own 80.77% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Further Reading: Why Dividend Stocks May Be Right for You

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.